Ovarian cancer is considered a silent killer due to the lack of clear symptoms and efficient
diagnostic tools that often lead to late diagnoses. Over recent years, the impelling need for …

Background Breast cancer (BC) is the most common cancer among women and it is
responsible for more than 40,000 deaths in the United States and more than 500,000 deaths …

Background Apatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth
factor receptor-2 (VEGFR2), and has shown encouraging therapeutic effects in various …

Epithelial ovarian cancer (EOC) is a fatal gynecologic cancer, and its poor prognosis is
mainly due to delayed diagnosis. Therefore, biomarker identification and prognosis …

Ovarian cancer stands as the deadliest gynecologic malignancy, responsible for nearly 65%
of all gynecologic cancer-related deaths. The challenges in early detection and diagnosis …

Mounting evidence suggests that immune cell infiltration within the tumor microenvironment
(TME) is a crucial regulator of carcinogenesis and therapeutic efficacy in ovarian cancer …

Highlights•Epigenetic alterations are an emerging factor in colorectal carcinogenesis.•The
discovery of epigenetic pathways constitutes a major advance in cancer biomarker …

Abstract Purpose Assessment of miR-424-3p mimic capability to sensitize SK-OV-3 and TOV-
21G ovarian cancer cells to cisplatin by decreasing the expression of galectin-3, which is an …

High‐grade serous ovarian carcinomas (HGSOC s) were among the tumours with an
unsatisfactory outcome of immune checkpoint inhibitors (ICI s). It is imperative to develop …

Ovarian cancer (OC) is a relatively fatal female reproductive malignancy. Since the
underlying causes are uncertain, it brings us to believe that both genetic and external factors …